Live data · NADAC + Part D CY24 · reviewed daily

Rizatriptan (MAXALT)

First FDA approval2012-06-25
Generic availableYes · 7 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$26.3M in CY2024 Part D spend1.1M claims · 356K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.335/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.339
Across all dosage forms in distribution.
Highest NADAC
$0.348
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Rizatriptan used for?

Rizatriptan is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Rizatriptan?

Yes. 18 ANDAs filed at FDA, 7 generic manufacturers currently shipping.

How much does my plan pay for Rizatriptan?

Across 329 Part D plans, Rizatriptan averages $0.339/unit (NADAC). Lowest available: $0.335/unit. Highest in distribution: $0.348/unit.

Is Rizatriptan on the FDA shortage list?

No. Rizatriptan is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.